Lumito AB is provided approximately MSEK 38.7 in cash through an over-subscribed rights issue and a decided over-allotment

Lumito AB (publ) announces today that the Company's new share issue amounting to approximately MSEK 35.7 has been subscribed to a total of 155 percent. The commitments from the guarantee consortium do therefore not have to be utilized. In addition, an over-allotment issue of MSEK 3.0 has been decided.

An extraordinary general meeting of Lumito AB (publ) held on 25 April 2019 resolved to approve the Board of Directors's proposal to conduct an issue of units with preferential rights for the shareholders, and further resolved to authorize the Board of Directors to decide on a possible over-allotment of up to 2,400,000 units. The new issue was to be comprised of 28,533,729 units, each one consisting of one share and one warrant, at a subscription price of SEK 1.25 per share (with the associated warrant included gratuitously).

In total, 44,355,790 units were subscribed, 19,979,306 of which with preferential rights and 24,376,484 of which without preferential rights. The full amount of the issue, 28,533,729 units, will therefore be alloted. The Board of Directors has also decided to utilize its mandate to conduct an additional directed issue, a so-called over-allotment, as previously laid out in the prospectus. This means that the Company conducts an issue of 2,400,000 additional units (MSEK 3.0) at a corresponding price per unit. In total, Lumito will therefore be provided approximately MSEK 38.7 in cash in proceeds from the issue, before issuance costs.

Upon registration of all of the newly issued units, the number of shares in the Company will total 59,467,458, and the number of Series TO2 warrants will total 30,933,729. The share capital will increase with SEK 773,343.225, to SEK 1,486,686.45. Minor adjustments of the number of shares and amounts set out above may occur in connection with the final registration with the Swedish Companies Registration Office.

Subscription of units with and without preferential rights took place between 15 May and 31 May 2019. Subscribers with subsidiary rights have been granted full allotment. The allotment of the units subscribed without preferential rights was performed in accordance with the principles stated in the prospectus for the issue. Notice on allotment of units subscribed without preferential rights will shortly be sent to those that were allotted units. Units are to be paid in accordance with the instructions on the contract note.

G&W Fondkommission has acted as financial advisor and Aktieinvest FK AB has been the issuer agent in connection with the issue.

As soon as the increase in share capital has been registered with the Swedish Companies Registration Office, paid subscription units (BTU) in the preferential rights issue will be transformed into new shares and warrants. Until then, trade in BTU:s will be performed on NGM Nordic MTF. Those that have been alloted units within the over-allotment issue will receive shares and warrants directly. These will not be delivered until the registration with the Swedish Companies Registration Office is finished, in connection with the date when paid subscription units (BTU) from the rights issue are transformed into new shares and warrants. The commencement of trading of new shares and series TO2 subscription warrants will be announced in a separate press release.

This information is information that Lumito AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, on 4 June 2019, at 8:30 AM.

For more information contact:

Lumito AB (publ), CEO Stefan Nilsson, telefon +46 767 78 59 05, sn@lumito.se

Lumito in brief
Lumito is specialised in research and development of imaging technologies for medical applications. The technology is based on so called UCNP:s (Up Converting Nano Particles) and is aiming to increase image quality in biomedical applications. Lumito´s IPR covers imaging with high quality of for instance tissue samples, with UCNP:s as markers. The technology has several possible application areas, but Lumito has initially decided to focus on digital pathology. Lumito has an agreement with TTP plc (The Technology Partnership) in Cambridge, UK, regarding development of instruments and staining reagents. Lumito’s share Lumito and warrant Lumito TO1 are traded at the NGM Nordic MTF marketplace.

Tags:

Subscribe

Documents & Links